Levi & Korsinsky Investigates Possible Securities Fraud Violations by Arvinas, Inc. (ARVN)

Levi & Korsinsky, a well-known securities litigation firm, has opened an investigation into Arvinas, Inc. (NASDAQ: ARVN) for potential violations of federal securities laws. This action comes after Arvinas, in partnership with Pfizer, Inc., announced a delay in the anticipated completion date of their Phase 3 trial for vepdegestrant, a breast cancer therapy. The expected completion date has been pushed from November 2024 to January 2025, with top-line data now expected in the first quarter of 2025.

Following this news, the stock price of Arvinas experienced a decline in intraday trading on the same day. Investors looking for more information can visit the investigation page at zlk.com/pslra-1/arvinas-inc-lawsuit-submission-form?prid=113366&wire=1 or reach out to Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by phone at (212)363-7500.

Levi & Korsinsky, a firm known for securing substantial settlements for shareholders, has a strong track record of winning complex securities litigation cases over the past 20 years. With a dedicated team of over 70 employees, Levi & Korsinsky stands out as one of the top securities litigation firms in the United States. It has consistently ranked in ISS Securities Class Action Services’ Top 50 Report for the past seven years. It’s important to note that prior results do not guarantee similar outcomes.

For any inquiries or to learn more about the investigation, you can contact Levi & Korsinsky at 33 Whitehall Street, 17th Floor, New York, NY 10004, or visit their website at zlk.com.

Please consult the original press release on accesswire.com for more details. This article was created independently by Levi & Korsinsky and not by the Markets Insider or Business Insider editorial teams.